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Expression of the multiple drug resistance associated genes: MRP1, 
LRP and BCRP among leukemia patients in Gaza strip. 
 
ABSTRACT 
Hematological neoplasms are usually sensitive to chemotherapy, but with 
relatively high rate of relapse. Cell resistance to drugs is a major determinant of 
response to chemotherapy and its detection may be of clinical relevance. The 
role of expression of transmembrane carriers such as multidrug resistance 
related Protein 1 (MRP1), breast cancer resistance protein (BCRP) and lung 
resistance protein (LRP) genes in neoplastic cell survival and risk of relapse for 
leukemia patients was previously documented. Therefore, the aim of this study 
was to estimate the level of expression of MRP1, BCRP, and LRP genes in 
blood cells of leukemia patients in Gaza strip by quantitative real-time RT-PCR 
technique, and to investigate any correlation between the expression of these 
genes and other previous and current clinical findings of the patient. 
Blood samples were collected from 70 leukemia patients (40 males and 30 
females) admitted in the Hematology Departments of Al-Shefa hospital, the 
European Gaza Hospital and AL-Nasser pediatric hospital in Gaza strip. The 
specimens were collected during the period between May to November, 2009. 
Patients medical data were obtained from their records in the relevant 
hospitals, and included personal, medical, management and family information 
(e.g. age, type of disease, severity of case, date of diagnosis of disease, types , 
protocols of treatments, prognosis, previous tests results and others).  A control 
group of 35 normal healthy individuals was included mainly to correct for any 
inter-individual expression difference as a result of gender and age variation. 
This group was also used to compare the levels of gene expression in normal 
and leukemia patients. The level of expression of MRP1, LRP, and BCRP 
genes in cells of leukemia patients were quantitated by quantitative Real Time-
PCR technique and normalized by the expression level of an endogenous 
control gene porphobilinogen deaminase (PBGD). The SPSS version 15 was 
used for statistical analysis. 
 
 IV
Five types of leukemia, from different areas of Gaza strip, were included in this 
study. Thirty cases (42.9%) were acute lymphoblastic leukemia, 5 cases (7.1%) 
acute myeloblastic leukemia, 12 cases (17.1%) chronic lymphoblastic leukemia, 
22 cases (31.4%) chronic myeloblastic leukemia and 1 case (1.4%) small 
lymphoblastic leukemia.  
The mean age of cases was 32.9 ±28.2 years and the mean age of controls 
was 27.2 ±18.8 years.  
MRP1 and LRP but not BCRP mean level of gene expression was significantly 
higher in leukemia group than normal control group.  MRP1 gene expression in 
ALL patients was lower than all types of leukemia and significantly lower than in 
AML (P=0.00). LRP gene expression was significantly higher in AML and CML 
patients than in control group (AML: P=0.021 and CML: P=0.001). LRP gene 
expression in ALL patients were significantly lower than CML patients 
(P=0.024); and in CML patients higher than CLL patients (P=0.046). There was 
no statistically significant difference between leukemia types in BCRP gene 
expression levels. MRP1 and LRP mean levels of expression in remission was 
less than with no remission patients and this decrease of expression was 
statistically significant (MRP1: P=0.003 & LRP: P=0.050). The mean level of 
BCRP gene expression in remission patients was also less but with no 
statistical significance. When comparing the level of MRP1, LRP and BCRP 
according to management protocols and gender of patient no significant 
relationship was established. 
The outcome of the current study indicates that higher levels of MRP1, LRP and 
BCRP expression are correlated with chemotherapeutic treatment failure of 
leukemia patients. Therefore we suggest these factors to be included in the 
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Cancer is a group of diseases in which the body's cells become abnormal and 
divide without control. Cancer cells may invade nearby tissues, and they may 
spread through the blood stream and lymphatic system to other parts of the 
body. 
Cancer is considered one of the most important health problems in both 
developing and developed countries for its high incidence, cost and associated 
mortality. Cancer is the third leading cause of death among Palestinians after 
cardiovascular diseases and cerebrovascular disease, and it is a major cause of 
morbidity among Palestinian population (1). 
Bone marrow cancer is the fifth most common type of cancer in Gaza strip after 
Trachea, Bronchus & lung cancer, colo-rectal and anus cancer, breast cancer 
and Brain & other nervous system cancer (2). In children, the most common 
cases of pediatric cancers are lymphomas (30.7%), the first leading cause of 
cancer morbidity in male children; and bone marrow (27.8%), the first one in 
female children under 15 years old (1). 
Leukemia is a form of cancer that starts in the blood-forming tissue such as the 
bone marrow in which the body produces too many white blood cells, and is 
usually characterized by the presence of the abnormal cells in peripheral blood. 
In a small number of patients, they are not found (aleukemic leukemia). There 
are two major kinds of leukemia: chronic and acute (3). Acute leukemia is a 
rapidly progressing disease involving the proliferation and accumulation of 
immature red and white blood cells and platelets (i.e., blasts and other very 
early cells). Accordingly, these cells cannot carry out their normal functions. 
Acute leukemia has a rapid course lasting for two to four months without 
treatment, and usually affects younger age groups. It is divided into two 
categories, depending on the cell type involved. If the disease involves the 
 
 ʹ
lymphocytes it is called acute lymphocytic leukemia (ALL), but if it affects the 
myelocytes it is known as acute myelogenous leukemia (AML).  
Chronic leukemia progresses more slowly and mostly affects older adults. It 
permits greater numbers of fully developed blood cells to grow, allowing these 
cells to carry out some of their normal functions. This type of leukemia is also 
divided in two major types; chronic lymphocytic leukemia (CLL) and chronic 
myelogenous leukemia (CML) (4). 
Although leukemia collectively affects approximately 10 times more adults than 
children, it is the most common type of cancer among children, with ALL 
accounting for approximately 78% of all childhood leukemia. The most common 
type of leukemia in adults is AML, followed by CLL, CML and ALL (4). The only 
Palestinian comprehensive cancer report was published by the Palestinian 
Ministry of Health and covered the period 1995-2000 (1). In that period ALL 
accounted for 36.5% of leukemia cases in Gaza Strip; AML accounted for 
20.7%; plasma cell multiple myeloma (PML) accounted for 15.2% of cases; CLL 
accounted for 12.5% of cases and CML accounted for 15.2% of cases. 
All types of leukemia are managed mainly by chemotherapy. In the period 1995-
2000 the proportional distribution of marrow cancer therapy in Gaza showed 
that chemotherapy was applied for 95% of total treated cases and radiation in 
23.5%, in addition to other less commonly used types of therapies like 
biological, surgery, and bone marrow transplantation (1). In Gaza strip hospitals 
the protocols for chemotherapy treatment applied upon leukemia patients 
depend on age, weight, WBCs count, stage and type of disease in direction to 
choose the specific anticancer drug. 
According to the chemotherapy protocol for pediatrics non-Hodgkin's 
lymphoma, the drugs used in treatment of ALL in Oncology Departments of 
Gaza hospitals are methotreaxate, prednisolone, vincristine, epirubicine, L-
asparaginase, cyclophosphoamide, cytosinearabinoside and 6-mercaptopurine 
which are all administered intravenously. The dose of drug depends on, age, 
weight, and most importantly the phase of disease. 
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 In other types of leukemia like AML, CML, and CLL which affect adults more 
than children, the drugs used are cytarabine, daunorubicin, hydroxyurea, 
busulfan, cytosine arabinoide, Imatinibe mesylate, interferone-alfa and 
fludarabiune. These drugs are taken by oral and intravenous roots (5). 
There are a number of strategies in the administration of chemotherapeutic 
drugs used today. Chemotherapy may be given with a curative intent or it may 
aim to prolong life or to palliate symptoms. Combined modality chemotherapy is 
the use of drugs with other cancer treatments, such as radiation therapy or 
surgery. Most cancers are now treated in this way. Combination chemotherapy 
is a similar practice which involves treating a patient with a number of different 
drugs simultaneously. The drugs differ in their mechanism and side effects. The 
biggest advantage is minimizing the chances for resistance developing to any 
one agent. 
Chemotherapy of cancer and especially leukemia is frequently associated with 
dangerous side effects. Furthermore, failure of therapy is one of the major 
obstacles facing leukemia managements. Treatment failure in acute leukemia 
may be caused by several different factors, the main determinants of treatment 
failure in Acute leukemia include: low cellular sensitivity to cytotoxic drugs 
(cellular drug resistance); increased proliferation potential of leukemia cells 
between courses of chemotherapy (regrowth resistance) and low systemic 
exposure of antileukemic drugs(pharmacokinetic resistance) (6). 
Drug resistance is setting one of the major obstacles in the success of 
treatment and is an important cause of death in acute leukemia. Drug 
resistance, refers to the ability of cancer cell to resist the action of anticancer 
drugs and inhibit its action. Such resistance may be present before beginning 
treatment or may develop during chemotherapy. Drug resistance that extends to 
structurally and functionally unrelated drugs is termed multidrug resistance 
(MDR) (7). The ATP-binding cassette (ABC) transporter super family contains 
membrane proteins that translocation a wide variety of substrates across extra- 
and intracellular membranes including drugs. 
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ABC genes represent the largest family of transmembrane (TM) proteins. These 
proteins bind ATP and use the energy to drive the transport of various 
molecules across all cell membranes (8-10). Proteins are classified as ABC 
transporters based on the sequence and organization of their ATP-binding 
domains. Overexpression of certain ABC transporters occurs in cancer cell lines 
and tumors that are multidrug resistant, and there are a number of important 
ABC genes which play an important role in MDR of cancer cells, including the 
multidrug resistance associated protein (MRP1), the lung resistance protein 
(LRP) and the breast cancer resistance protein (BCRP).  
1.2 Objective of the study 
Overall objective: 
To determine the level of expression of the multiple drug resistance associated 
genes: MRP1, LRP and BCRP among leukemia patients, in Gaza strip. 
Specific objectives: 
1. To investigate any correlation between the expression of these genes 
and clinical variables of the patients like: age, gender, living area and 
leukemia type. 
2. Investigate the correlation between expression of these genes and 
disease management and remission.  
1.3 Significance 
To my knowledge this study will be the first to deal with multidrug resistance in 
cancer and particularly in leukemia patients in Palestine. The establishment of a 
clinically relevant expression assessment of multidrug resistance genes will aid 
as a prognostic indicator of chemotherapy responsiveness in human 
malignancies. It will also aid in defining therapeutic target(s) for reversing 
multidrug resistance in patients. In addition, it will highlight the need for 








Cancer is a collective term used for a group of diseases that are characterized 
by the loss of control of the growth, division, and spread of a group of cells, 
leading to a primary tumor that invades and destroys adjacent tissues. It may 
also spread to other regions of the body through a process known as 
metastasis, which is the cause of 90% of cancer deaths (11). Cancer remains 
one of the most difficult diseases, and incidence is increasing due to the ageing 
of population in most countries, but especially in the developed ones. 
Cancer is normally caused by abnormalities of the genetic material of the 
affected cells. Tumorigenesis is a multistep process that involves the 
accumulation of successive mutations in oncogenes and suppressor genes that 
deregulates the cell cycle. Tumorigenic events include small-scale changes in 
DNA sequences, such as point mutations; larger-scale chromosomal 
aberrations, such as translocations, deletions, and amplifications; and changes 
that affect the chromatin structure and are associated with dysfunctional 
epigenetic control, such as aberrant methylation of DNA or acetylation of 
histones (12).  About 2,0003,000 proteins may have a potential role in the 
regulation of gene transcription and in the complex signal-transduction 
cascades that regulate the activity of these regulators. 
Cancer is not only a cell disease, but also a tisular disease in which the normal 
relationships between epithelial cells and their underlying stromal cells are 
altered (13).  
Cancer is presently responsible for about 25% of deaths in developed countries 
and for 15% of all deaths worldwide. It can therefore be considered as one of 
the foremost health problems, with about 1.45 million new cancer cases being 
expected yearly (11). So, cancer is considered one of the most important health 
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problems in both developing and developed countries for its high incidence, 
cost and associated mortality. 
2.2 Leukemia 
The acute leukemia is a heterogeneous group of neoplasm's arising from 
transformation of uncommitted or partially committed hematopoietic stem cells 
(14). Acute leukemia represents a group of complex and heterogeneous 
diseases, which are characterized by accumulation of malfunction and 
immature leukemia blasts in the peripheral blood and the bone Marrow. 
Recurring chromosomal abnormalities found in over half of patients are critical 
for classification of the diseases, risk stratification, and design of treatment 
regiments (15). Acute leukemia is currently classified pragmatically by a 
combination of differentiation, pathogenesis, and genetic abnormalities. Lineage 
assignment (myeloid vs. lymphoid) is based on morphology features, 
cytochemistry, and immunophenotyping. This classification of each group of 
leukemia has become essential, as treatment is evolving for specific genetic 
and pathogenetic groups of disease (16). There are two major kinds of 
leukemia: chronic and acute. Acute leukemia is a rapidly progressing disease 
involving the proliferation and accumulation of immature red and white blood 
cells and platelets (i.e., blasts and other very early cells). 
Acute leukemia has a rapid course lasting for two to four months without 
treatment, and usually affects younger age groups. It is divided into two 
categories, depending on the cell type involved. If the disease involves the 
lymphocytes it is called acute lymphocytic leukemia (ALL), but if it affects the 
myelocytes it is known as acute myelogenous leukemia (AML).  
Chronic leukemia progresses more slowly and mostly affects older adults. It 
permits greater numbers of fully developed blood cells to grow, allowing these 
cells to carry out some of their normal functions. This type of leukemia is also 
divided in two major types; chronic lymphocytic leukemia (CLL) and chronic 




2.2.1 Treatment of leukemia 
Cancer therapy is based on surgery and radiotherapy, which are, when 
possible, rather successful regional interventions, and on systemic 
chemotherapy. Approximately half of cancer patients are not cured by these 
treatments and may obtain only a prolonged survival or no benefit at all. The 
aim of most cancer chemotherapeutic drugs currently in clinical use is to kill 
malignant tumor cells by inhibiting some of the mechanisms implied in cellular 
division and the antitumor compounds developed through this approach are 
cytostatic or cytotoxic (11). 
Treatment is usually given soon after diagnosis and classification type and 
stage to all kinds of acute and chronic leukemia's. There are four main types in 
treatment of leukemia which are chemotherapy, radiotherapy, immunotherapy, 
bone marrow transplantation. 
Treatment depends on prognostic factors, including the total white blood cells 
counts (WBCs), morphology of cells, cytogentics analysis, type of leukemia, 
response to treatment, the patient's age, whether leukemia cells are present in 
the cerebrospinal fluid, and health status of patient.  
The chemotherapy treatment is more common in all leukemia patients. Most 
cytotoxic chemotherapy drugs work by disrupting the ability of cancer cells to 
grow and multiply. They can be administrated by several routes. When given by 
mouth, the drugs are rapidly absorbed into the blood stream from the gut and 
carried throughout the body to reach the cancer cells. Drugs that cannot be 
given by mouth because they are not well absorbed are injected into 
subcutaneous fat or muscles or infused directly into a vein; that way they reach 
cancer cells rapidly and can begin to work without delay (17). 
2.2.1.1 Chemotherapy 
Chemotherapy refers to treatment of disease by chemicals that kill cells, both 
good and bad, but specifically cancerous tumors. In popular usage, it refers to 
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antineoplastic drugs used to treat cancer or the combination of these drugs into 
cytotoxic standardized treatment regimen. 
Most commonly, chemotherapy acts by killing cells that divide rapidly, one of 
the main properties of cancer cells. This means that it also harms cells that 
divide rapidly under normal circumstances: cells in the bone marrow, digestive 
tract and hair follicles (18). 
A. Antineoplastic drug 
Any of several drugs that control or kill neoplastic (cancer) cells. All have 
unpleasant side effects that may include nausea and vomiting and hair loss and 
suppression of bone marrow function (19). 
Doxorubicin for example, is antineoplastic drug, (trade name Adriamycin) also 
known as hydroxydaunorubicin used in cancer chemotherapy (Figure 2.1). It is 
an anthracycline antibiotic, closely related to the natural product daunomycin, 
and like all anthracyclines it works by intercalating DNA by intercalation and 
inhibition of macromolecular biosynthesis (20).  
 
Figure 2.1 Chemical Structure of Doxorubicin drug (20). 
 
It inhibits the progression of the enzyme topoisomerase II, which unwinds DNA 
for transcription. Doxorubicin stabilizes the topoisomerase II complex after it has 
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broken the DNA chain for replication, preventing the DNA double helix from 
being resealed and thereby stopping the process of replication (20). 
It is commonly used in the treatment of a wide range of cancers, including 
hematological malignancies, many types of carcinoma, and soft tissue 
sarcomas. The drug is administered intravenously, in the form of hydrochloride 
salt. 
All cytotoxic chemotherapy drugs have their own specific modes of action; some 
kill cancer cells only when they are multiplying, while others kill all cancer cells. 
They can be used singly or in groups that work together, referred to as 
combination chemotherapy. Most treatment plans for hematological cancers 
include combination chemotherapy and, occasionally, radiation therapy, 
immunotherapy and the newer treatment; monoclonal antibodies. Treatment 
protocols for hematological malignancies prepared according to many factors 
that must be take before drug choice for treatment, these factors related to 
severity of disease, status of patient, body response to treatment,  age, weight, 
change in organ function, increase the risk of toxicity and WBCs count (21, 22).  
Important information necessary for the optimal use of these cancer drugs 
includes: a. mechanism of action;   b. pharmacology, including bioavailability, 
routes of elimination, and important drug interactions; and c. toxicities. Table 










Table 2.1 Classes of chemotherapeutic Agents.  

























































































For an antineoplastic drug to be active it must (a) be taken up into a cancer cell 
and (b) be converted into an active agent. It must then make its way within the 
cell to its target without being (c) metabolically inactivated, (d) chemically 
inactivated, or (e) excreted from the cell. Once it interacts with its cellular target 








Figure 2.2. Potential pathways for antineoplastic drug disposition in tumor cells. For a drug to 
be effective, the drug, or its active metabolite, must reach its target site within the cell. Possible 
steps required for a drug to reach its receptor or to be inactivated include: (1) uptake into a cell 
through a particular transport protein; (2) enzymatic conversion of the drug to an inactive 
metabolite; (3) enzymatic conversion of the drug to its active metabolite; (4) binding of an active 
metabolite by a cellular protein or thiol, thereby inactivating drug; (5) excretion of the drug from 
the cell via an efflux transport pump; (6) alteration in the genetic makeup of the cell, changing 
the drug receptor site or number; and (7) changes in the ability of a cell to repair damage of a 
drug at its receptor (23). 
 
B. Mechanism of antineoplastic drug action 
Antineoplastic agents interfere with some essential step required for all cell 
growth or division. The initial target of antineoplastic drugs varies widely, from 
direct attack on the DNA molecule to inhibition of the formation of mitotic spindle 
needed for cell division.  All antineoplastic agents cause a disruption in a normal 
cellular process so significant that it requires the cell to either quickly repair the 
damage or initiate the process of apoptosis ( programmed cell death) so, all of 
these drugs lead to cell death through initiation of apoptosis. 
Apoptosis is the normal physiologic process of cellular suicide, which occurs in 





C.  Cytotoxic drugs initiate apoptosis 
An understanding of events occurring in normal cell cycle is important. The cell 
cycle is composed of four distinct phases during which the cell prepares for and 
undergoes mitosis. The G1 phase consists of cells that have recently completed 
division and are committed to continued proliferation. After a variable period of 
time, these cells begin to synthesize DNA, marking the beginning of the S 
phase. After DNA synthesis is complete, the end of the S phase is followed by 
the premitotic rest interval called the G2 phase. Finally, chromosome 
condensation occurs and the cells divide during the mitotic M phase. Mitosis 
phase (M-phase), take up only a small part of cell cycle, in most, if not all, cells, 
the cell cycle is temporarily halted during the G1-S-phase checkpoint  and at the 
G2-M-phase checkpoint. At these times, cells determine whether to continue 
into S-phase, initiate the process of apoptosis, or undergo DNA repair (25). 
Passage into a new phase of cell cycle requires activation of a series of 
enzymes called cyclin-dependent kinases, which activate another enzymes (the 
cyclins) (26). 
If cells are damaged by chemotherapeutic agents and are unable to repair the 
damage, apoptosis is initiated at the G1-S or G2-M checkpoint, provided that 
the mechanisms for apoptosis are in place. However, the presence, or absence, 
of apoptotic proteins is as important as the initial interaction between a cytotoxic 
drug and its effecter in determining whether tumor cell kill occurs. The 
antineoplastic agents provide the initial trigger for beginning the pathway to 









Figure 2.3. Potential pathways involved in cytotoxicity induced by chemotherapy. 
Chemotherapeutic drugs or growth-factor deprivation damages cells. Cells are arrested at the 
G1S checkpoint. If the damage is sublethal, it may be repaired and the cell proceeds to S 
phase. If significant DNA damage is present, the process of programmed cell death is initiated. 




D.  Factors affecting the activity of drug  
Several factors affecting the function of drug within the cell from the drug 
deposition within the body from the time it is administered until it reaches its 
target site, these factors are critical to achieving an antitumor response. For a 
drug to function, it must be taken into the body, and avoid being cleared from 
the body by metabolism or excretion. It must reach its site of action in active 
form without being inactivated by protein binding (Figure 2.2). 
Pharmacokinetics means how a patient will handle a given dose of drug (27). 
The four most important pharmacokinetic parameters are: 
a. Bioavailability (drug absorption), drugs are different in bioavailability, 
which is the percentage of a dose of drug that reaches the plasma 
compartment, so the drug given intravenously, have 100% bioavailability. 
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b. Volume of distribution, after a drug reaches the bloodstream, it is 
distributed into tissues, distribution affected by drug binding to plasma 
proteins (usually albumin or á-acid glycoprotein). 
c. Clearance where a drug can be removed per unit of time. 
d. Drug half-life (28-34). 
2.2.1.2 Types of chemotherapeutic drugs 
Chemotherapeutic agents are classified by mechanism of action and the 
majority of chemotherapeutic drugs can be divided into: alkylating agents, 
antimetablolites, plant alkaloids, topoisomerase inhibitors, and antitumor 
antibiotics. All of these drugs affect cell division or DNA synthesis and cause 
cancer cell death (18). 
A. Alkylating agents 
Are so named because of their ability to add alkyl groups to many 
electronegative groups under intercellular conditions (aqueous solution, 37Cº, 
pH 7.4). DNA alkylating agents interact with resting and proliferating cells in any 
phase of the cell cycle, but they are more cytotoxic during the late G1 and S 
phases. Alkylation prevents DNA replication and RNA transcription from the 
affected DNA. It also leads to the fragmentation of DNA by hydrolytic reactions 
and also by the action of repair enzymes when attempting to remove the 
alkylated bases (35).  
They stop tumor growth by cross-linking guanine nucleobases in DNA double-
helix directly attacking DNA. This makes the strands unable to uncoil and 
separate, necessary in DNA replication, and the cells can no longer divide. 
These drugs acts mainly nonspecifically, some of them require conversion into 
active substances in vivo (e.g. cyclophosphamide). Examples of these agents 







Antimetabolites can be defined as analogs of naturally occurring compounds 
that interfere with their formation or utilization, thus inhibiting essential metabolic 
routes.  Anti-metabolites as purine or pyrimidine- analogues which are the 
building blocks of DNA. They prevent these substances from becoming 
incorporated into DNA during the "S" phase (of the cell cycle), stopping normal 
development and division. An important example is 5-Fluoro Uracil (5FU), which 
inhibits thymidylate synthase. Fludarabine inhibits function of multiple DNA 
polymerases, DNA primase, DNA ligase I and is S phase-specific (since these 
enzymes are highly active during DNA replication). Methotrexate (being folate 
antagonist) inhibits dihidrofolate reductase, enzyme essential for purines and 
pyrimidines synthesis (18). 
 
C.  Plant alkaloids 
These alkaloids are derived from plants and block cell division by preventing 
microtubule synthesis and mitotic spindle formation, which is vital for cell 
division and without them it can not occur.  Microtubules are the main target of 
cytotoxic natural products. Drugs acting on microtubules bind to several sites of 
tubulin and at different positions of the microtubules but they all suppress 
microtubule dynamics, thereby blocking mitosis at the metaphase/anaphase 
transition and inducing cell death. 
The main examples are vinca alkaloids such as vincristine, vinblastine and 
vinorelbine which bind to specific sites on tubulin, inhibiting the assembly of 
tubulin into microtubules. The new group of taxanes paclitaxel (from Taxis 
brevifolia) with its synthetic derivate (docataxel) inhibits cell division by 






D. Topoisomerase inhibitors 
Identical loops of DNA having different numbers of twists are topoisomers, that 
is, molecules with the same formula but different topologies, and their 
interconversion requires the breaking of DNA strands. DNA topoisomerases are 
enzymes that regulate the three-dimensional geometry (topology) of DNA, 
leading to the interconversion of its topological isomers and to its relaxation. 
This is related to the regulation of DNA supercoiling, which is essential to DNA 
transcription and replication, when the DNA helix must unwind to permit the 
proper function of the enzymatic machinery involved in these processes (36).  
Topoisomerases are essential enzymes which maintain the topology of DNA. 
Inhibition of type I or type II topoisomerases interferes with both transcription 
and replication of DNA by upsetting proper DNA supercoiling. Some type I 
topoisomerase inhibitors include camptothecins: irinotecan and topotecan. 
Examples of type II inhibitors include amsacrine, etoposide, etoposide 
phosphate, and teniposide. The latter are semisynthetic derivatives of 
epipodophyllotoxins, alkaloids naturally occurring in the root of mayapple 
(Podophyllum peltatum) (18). 
E. Antitumour antibiotics 
Many anticancer drugs in clinical use (e.g. anthracyclines, mitoxantrone, and 
dactinomycin) interact with DNA through intercalation, which can be defined as 
the process by which compounds containing planar aromatic or heteroaromatic 
ring systems are inserted between adjacent base pairs perpendicularly to the 
axis of the helix and without disturbing the overall stacking pattern due to 
WatsonCrick hydrogen bonding. 
There are many differing antitumour antibiotics, but generally they prevent cell 
division by several ways: (1) binding to DNA through intercalation between two 
adjacent nucleotide bases and making it unable to separate, (2) inhibiting 
ribonucleic acid (RNA), preventing enzyme synthesis and (3) interfering with cell 
replication. They are products of various strains of the soil fungus 
Streptomyces. Examples are anthracyclines (doxorubicin and daunorubicin 
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(which also inhibit topoisomerase II), actinomycin, bleomycin, mitomycin and 
plicamycin. Bleomycin acts in unique way through oxidation of a DNA-
bleomycin-Fe (II) complex and forming free radicals, which induce damage and 
chromosomal aberrations (18). 
2.3 Drug resistance 
It is obvious that cancer chemotherapy is a very difficult task. One of its main 
associated problems is the nonspecific toxicity of most anticancer drugs due to 
their biodistribution throughout the body, which requires the administration of a 
large total dose to achieve high local concentrations in a tumor. Drug targeting 
aims at preferred drug accumulation in the target cells independently of the 
method and route of drug administration (37). One approach that allows 
improving the selectivity of cytotoxic compounds is the use of prodrugs that are 
selectively activated in tumor tissues, taking advantage of some unique aspects 
of tumor physiology, such as selective enzyme expression, hypoxia, and low 
extra cellular pH. More sophisticated tumor-specific delivery techniques allow 
the selective activation of prodrugs by exogenous enzymes (gene-directed and 
antibody-directed enzyme prodrug therapy). Furthermore, the increased 
permeability of vascular endothelium in tumors (enhanced permeability and 
retention, EPR effect) permits that nanoparticles loaded with an antitumor drug 
can extravasate and accumulate inside the interstitial space, where the drug 
can be released as a result of normal carrier degradation (38).  
Another problem in cancer chemotherapy is drug resistance. After the 
development of a resistance mechanism in response to a single drug, cells can 
display cross-resistance to other structural and mechanistically unrelated drugs, 
a phenomenon known as multidrug resistance (MDR) in which ATP-dependent 
transporters has a significant role (39). Resistance to anticancer drugs may be 
intrinsic resistance present before treatment or acquired developed during 
chemotherapy treatment.  
During disease progression, leukemia cells acquire a number of genetic 
alterations, most probably because of increased genomic instability, that may 
explain the aggressive phenotype, chemotherapeutic drug resistance, and poor 
 
 ͳͺ
prognosis. Despite the exciting results obtained with drugs like imatinibe 
mesylate, CML patients eventually show resistance at rate of 80% in blastic 
phase, 40-50% in acute phase, and 10% in chronic phase post-interferon á 
failure, at 2 years (40). Identification of the molecular basis of resistance is 
important, because it could provide insight into disease progression and into the 
design of novel therapeutic strategies to prevent and overcome treatment 
resistance. 
Drug resistance is setting one of the major obstacles in the successful treatment 
and is an important cause of death in acute leukemia. Drug resistance, refers to 
the ability of cancer cell to resist the action of anticancer drug and inhibit its 
action. Such resistance may be present before beginning treatment or may 
develop during chemotherapy. Drug resistance that extends to structurally and 
functionally unrelated drugs is termed multidrug resistance (MDR) (41). 
2.3.1 Classification of drug resistance 
The efficacy of cytostatic antineoplastic therapy is determined by a sequential 
cascade of events, including drug delivery, drug-target interaction and the 
induction of cellular damage. The first part of this cascade corresponds to the 
pharmacological resistance, and up to now has been the most widely studied 
mechanism of resistance. Classically, resistance is divided into extrinsic and 
intrinsic causes (42). 
■ Extrinsic resistance corresponds to the inability of the drug to reach the 
tumor cell: this is the case when the bioavailability of the oral form varies greatly 
from patient to patient, as with 6-mercaptopurine in ALL (43). Defects in tumor 
vascularisation, frequently observed in solid tumors, are also probably relevant 
for hematological malignancies (44).  
■ Intrinsic resistance is directly due to the properties of the tumor cell. This 
phenomenon can be observed in vitro, and can be classified as simple 
resistance, when the cells are resistant to only one drug, or as multidrug 
resistance, when a cross-resistance is observed for chemostatic drugs with 
different biochemical targets. This latter type of resistance is mainly observed in 
patients, and can be due to several mechanisms. The underlying 
 
 ͳͻ
pharmacological mechanism corresponds mainly to an active efflux of the drugs 
out of the tumor cells. Molecular profiles giving rise to broader forms of 
resistance are now under investigation, and it is believed that a defect in drug-
induced apoptosis is at least partly responsible. This could be due to increases 
in anti-apoptotic signals (survival signals from the micro-environment) and/or 
increases in anti-apoptotic proteins (ex: bcl-2) or decreases in pro-apoptotic 
proteins (ex: bax) (Figure 2.4) (42). 
 
Figure 2.4. Drug resistance in leukemia (42) 
 
2.3.2 Mechanisms of drug resistance 
Thirty-one years ago, Goldie and Coldman proposed a mathematical model for 
drug resistance, assuming that selected subclones of cancer cells eventually 
became resistant to chemotherapeutic drugs, owing to a high spontaneous 
mutation rate (45). These cells could escape the effect of cytotoxic drugs, 
through decreased uptake, increased catabolism, decreased transformation of a 
prodrug, modification of drug target, increase in DNA repair or resistance to 
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drug-induced apoptosis. Over the last 25 years, experimental models and 
clinical research have identified several causes of drug resistance in tumors 
(46).  
2.3.3 Multidrug resistance 
It was clinically observed that tumor cells resistant to a class of drugs, are 
usually also cross-resistant to chemotherapy with a different target. This 
phenomenon, called MDR, was described in vitro by Biedler and Riehm during 
the 1970s in Chinese hamster ovary cells and is now recognized as a most 
frequent phenotype developed in cultured tumor cells exposed to anthracyclines 
or vinca alkaloids (47). This MDR phenotype confers to the cells cross-
resistance to a broad range of structurally and functionally unrelated cytotoxic 
agents, sharing common properties: all are plant or microbial products, known 
as xenobiotics. The resistant tumor cells maintain lower intracellular drug 
concentrations than do their sensitive counterparts, and in the large majority of 
cases express transport proteins of the ABC (ATP-binding cassette) 
superfamily, responsible for the active efflux of these drugs. More recently, 
other mechanisms of resistance to a broad spectrum of drugs have been 
described: increase in DNA repair, and defects of drug-induced apoptosis, 
either due to strong survival signals delivered to the tumor cells by 
microenvironment, or because of a defect in the apoptosis pathway (figure 2.5). 
In man, mutations in genes encoding ABC transporters underlie diverse genetic 
diseases including cystic fibrosis, Tangier disease, DubinJohnson syndrome, 
sight disorders and adrenoleukodystrophy (48). 
2.4 ATP-binding cassette proteins (ABC) 
2.4.1 Transport across cell membranes 
The cell membrane is not simply a passive barrier, but provides the major 
interface between the cytoplasm of the cell and the extracellular milieu. Many 
proteins are ion channels and facilitators proteins which permit the passive 




ABC (ATP-binding cassette) proteins form one of the largest protein families 
and members of this family are found in all living organisms from microbes to 
humans. The wide-spread presence of these proteins with a relatively 
conserved structure and function suggests a fundamental role. The number of 
ABC transporters differs widely between species. Eukaryotic cells generally 
have fewer ABC transporters, presumably because other more sophisticated 
mechanisms for moving solutes across membranes have evolved.  
These transmembrane proteins are specialized in energy dependent cellular 
transport. The encoding MDR genes are highly conserved between species, 
from bacteria to man. The role of these proteins is mainly protection against 
xenobiotics (46). 
The minimum structure of the protein is an ABC unit of 200250 amino acids, 
consisting of consensus Walker A and B motifs and the ABC signature, located 
between the two Walker domains, for ATP binding, and six transmembrane 
domains (TMDs) (such as ABCG2). The more common structure consists of two 
ABC and 12 transmembrane domains (ABCB1 or P-glycoprotein), and a few 
members have five more transmembrane domains, with an external N-
termination (ABCC123) (Figure 2.5) (46). 
 
Figure 2.5 Structure of ABC proteins. TMD, transmembrane domain; ABC, ATP-




In the ABC proteins which act as primary active transporters, the transport 
function depends on the hydrolysis of ATP within the nucleotide-binding 
domains (NBDs). These cytoplasmic domains are attached to the intracellular 
regions of the TMDs, and a close interaction provides the functional connection 
between these two different domains. The nucleotide-binding domains bind 
cytoplasmic ATP and, in the active transporters, ATP hydrolysis ensures the 
energy for the uphill transport of a substrate. The specific, close interaction of 
NBDs with the TMDs provides the transmission gear of the conformational 
changes caused by substrate binding and the hydrolysis of ATP (49-51).  
2.4.2 Mechanism of transport 
Transport clearly involves major conformational changes and a conventional 
enzyme-like mechanism. The transport cycle is initiated by the interaction of 
substrate with a specific binding site(s) on the TMDs. Substrate binding induces 
a conformational change in the TMDs, which is transmitted to the NBDs to 
initiate ATP binding. There is now compelling, but not yet conclusive, evidence 
that it is ATP binding (rather than hydrolysis) which induces the major 
conformational changes responsible for altering the affinity and orientation of 
the substrate-binding site(s) such that substrate is released at the extracellular 
face of the membrane. Subsequent ATP hydrolysis and ADP/Pi release resets 
the transporter for another cycle. Both NBDs bind and hydrolyze ATP, and there 
is strong evidence in support of the alternating catalytic cycle mechanism. 
However, it is still unclear whether 1 or 2 ATP molecules are hydrolyzed per 
molecule of substrate transported; determination of this number, together with 
determination of the exact number of substrate-binding sites and the nature of 
the conformational changes involved, is crucial to complete elucidation of the 
transport cycle (48). 
2.4.3 Human ATP binding cassette gene subfamily 
The existing eukaryotic genes can be grouped into major subfamilies. A few 
genes do not fit into these subfamilies, and several of the subfamilies can be 
further divided into subgroups, (ABCA, ABCB, ABCC, ABCD, ABCE, ABCF and 
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ABCG). The human ABCA subfamily comprises 12 full transporters that are 
further divided into two subgroups based on phylogenetic analysis and intron 
structure (52, 53).  The first group includes seven genes dispersed on six 
different chromosomes ( ABCA1, ABCA2, ABCA3, ABCA4, ABCA7, ABCA12 
and ABCA13 ), whereas the second group contains five genes ( ABCA5, 
ABCA6, ABCA8, ABCA9 & ABCA10) arranged in a cluster on chromosome 
17q24 (54).  
The ABCB subfamily is unique in mammals in that it contains both full 
transporters and half transporters. Four full transporters and seven half 
transporters have currently been described as members of this subfamily. 
ABCB1 (MDR/PGY1) is the first human ABC transporter cloned and 
characterized through its ability to confer a MDR phenotype to cancer cells.  
The ABCC subfamily contains 12 full transporters with a diverse functional 
spectrum that includes ion transport, cell-surface receptor, and toxin secretion 
activities. The Cystic fibrosis transmembrane conductance regulator (CFTR,   
ABCC7) protein is a chloride ion channel that plays a role in all exocrine 
secretions; mutations in CFTR cause cystic fibrosis (55). ABCC8 and ABCC9 
proteins bind sulfonylurea and regulate potassium channels involved in 
modulating insulin secretion. The rest of the subfamily is composed of nine 
MRP-related genes. Of these, ABCC1, ABCC2, and ABCC3 transport drug 
conjugates to glutathionine and other organic anions. The ABCC4, ABCC5, 
ABCC11, and ABCC12 proteins are smaller than the other MRP1-like gene 
products and lack an N-terminal domain (56) that is not essential for transport 
function (57).  
The ABCD subfamily contains four genes in the human genome and two each 
in the Drosophila melanogaster and yeast genomes (58). All of the genes 
encode half transporters that are located in the peroxisome, where they function 
as homo- and/or heterodimers in the regulation of very long chain fatty acid 
transport.  
The ABCE and ABCF subfamilies contain gene products that have ATP-binding 
domains that are clearly derived from ABC transporters but they have no TM 
 
 ʹͶ
domain and are not known to be involved in any membrane transport functions 
(54).  
The human ABCG subfamily is composed of six reverse half transporters that 
have an NBF at the N terminus and a TM domain at the C terminus. The 
mammalian ABCG1 protein is involved in cholesterol transport regulation (59). 
Other ABCG genes include ABCG2, a drug-resistance gene; ABCG5 and 
ABCG8, coding for transporters of sterols in the intestine and liver; ABCG3, to 
date exclusively found in rodents; and the ABCG4 gene that is expressed 
predominantly in the liver. The functions of the last two genes are unknown. 
  
2.4.4 ATP binding cassette genes and human genetic disease 
Many ABC genes were originally discovered during the positional cloning of 
human genetic disease genes. There are 14 ABC genes have been linked to 
disorders displaying Mendelian inheritance like cystic fibrosis disease (ABCC7/ 
CFTR) and adrenoleukodystrophy (ABCD1/ALD) which are lethal diseases (60).  
Cells exposed to toxic compounds can develop resistance by a number of 
mechanisms including decreased uptake, increased detoxification, alteration of 
target proteins, or increased excretion. Several of these pathways can lead to 
multidrug resistance (MDR) in which the cell is resistant to several drugs in 
addition to the initial compound. This is a particular limitation to cancer 
chemotherapy, and the MDR cell often displays other properties, such as 
genome instability and loss of checkpoint control, that complicate further 
therapy. ABC genes play an important role in MDR, and at least six genes are 
associated with drug transport (61). 
Three ABC genes appear to account for nearly all of the MDR tumor cells in 
human,  these are ABCB1 /PGP/MDR1, ABCC1 /MRP1, and ABCG2 




Table 2.2 ABC transporters involved in drug resistance (54). 
Gene Substrates 
ABCB1 Colchicine, doxorubicin, etoposide, adriamycin, vinblastine, digoxin, 
saquinivir, paclitaxel 
ABCC1 Doxorubicin, daunorubicin, vincristine, VP16, colchicines, VP16, 
rhodamine 
ABCC2 Vinblastine, sulfinpyrazone 
ABCC3 Methotrexate, etoposide 
ABCC4 Nucleoside monophosphates 
ABCC5 Nucleoside monophosphates 
ABCG2 Mitoxantrone, topotecan, doxorubicin, daunorubicin, CPT-11, rhodamine 
 
2.4.5 ATP binding cassette transporters in tumor 
The multidrug resistance phenotype in tumors is associated with the 
overexpression of certain ABC transporters, termed MDR proteins. There are 
two ABC transporters, which have been definitely demonstrated to participate in 
the multidrug resistance of tumors: the multidrug resistance protein 1 
(MRP1/ABCC1) (62-64), and the mitoxantrone resistance protein (MXR/BCRP 
or ABCG2) (65). Furthermore, other human ABC proteins capable of actively 
transporting various compounds out of the cells may also be players in selected 
cases of multidrug resistance. These include the homologues of MRP1, MRP2-
MRP5. MRP2 and MRP3 seem to be key players in organic conjugate transport 
in various tissues, while MRP4 and MRP5, may have special functions as 
nucleoside transporters (66-70). The three major proteins involved in cancer 
MRP1 (multidrug resistance protein 1, ABCC1), lung resistance related protein 
(LRP) and the ABCG2 multidrug transporter (BCRP/ MXR). MDR1 and MRP1 
can recognize and transport a large variety of hydrophobic drugs, and MRP1 
can also extrude anionic drugs or drug conjugates (71-74).  
 
 ʹ͸
2.4.6 Multidrug resistance-associated protein (MRP) family (ABCC1
6 genes) 
The members of the ABCC family (MRP16; multidrug resistance-associated 
protein) have low homology (15%) with MDR1, and mainly act together with 
glutathione (figure 2.6).  
The ABCC1 (MRP1) gene maps to chromosome 16p13.1 and is expressed in 
tumor cells (75). ABCC1 is adjacent to the ABCC6 gene, and one of these 
genes undoubtedly arose by gene duplication. It encodes a full transporter that 
is the principal transporter of glutathione-linked compounds from cells. The 
ABCC1 gene was identified in the small cell lung carcinoma cell line NCI-H69, a 
multidrug-resistant cell that does not overexpress ABCB1 (76). The ABCC1 
pump confers resistance to doxorubicin, daunorubicin, vincristine, colchicines, 
and several other compounds, very similar profile to that of ABCB1 (77). 
However, unlike ABCB1, ABCC1 transports drugs that are conjugated to 
glutathione by the glutathione reductase pathway (75, 7881). Anthracyclines 
and vinca alkaloids, both weak organic bases, are conjugated with GSH, but are 
transported together with free GSH (Figure 2.6). MRP1 and -2 are particularly 
involved in the transport of chemotherapeutic agents in human cancer cells. 
 
Figure 2.6 MRP1 and -2 mediated drug efflux. Two modalities of drug transport are shown: (I) the GS-X 
complete is expelled by MRP: organic anions such methotrexate and ciplatine; (ii) Y is contransported by 
MRP in the presence of GSH: organic bases such as anthracyclines and alkaloids (46). 
2.4.6.1 MRP1 and leukemia 
 
 ʹ͹
The role of other MRPs is still under investigation. Few publications have 
concerned MRP in ALL, but all showed a measurable level of this protein at 
diagnosis, comparatively higher than in AML, and some cases showed an 
increase after treatment. CLL cells express variable levels of MRP at diagnosis 
and after treatment, but the amount of MRP does not influence the course of the 
disease (Table 2.3) (46). 
2.4.7 Lung resistance protein/major vault protein 
A wide variety of P-gp negative multidrug-resistant cancer cell lines expressed 
the lung resistance-related protein (LRP), identified as the major vault protein 
(MVP). Vaults are not ABC proteins, but cytoplasmic organelles, a small portion 
of which is localized in the nuclear membrane and nuclear pore complex, and 
are supposed to mediate the bidirectional transport of a variety of substrates 
between the nucleus and the cytoplasm. LRP was initially identified in an 
anthracycline-resistance, non-small cell lung cancer cell line that lacked P-gp 
overexpression (82). The LRP protein decrease the effectiveness of cytotoxic 
drugs, either by regulating nucleucytoplasmic transport of cytotoxic drugs away 
from the nucleus and/ or by involvement in sequestration of cytotoxic drugs in 
exocytotic vesicles (83) The LRP gene is located on chromosome 16 (16q11.2), 
close to the MRP1 gene, and encodes a 110-kDa protein (84). LRP has been 
reported to be involved in resistance to vincristine, doxorubicin and etoposide 
(85).   
In the majority of cases of AML, LRP/MVP is high, and detectable by RT-PCR, 
and the clinical significance of LRP expression becomes related to leukemia 
management (Table 2.3). In relapsed childhood ALL, LRP expression was 
associated with an increased in vitro resistance to daunorubicin. In summary, at 
least four ABC pumps and one non-ABC protein are able to expel several non-





Figure 2.7 Efflux pumps involved in drug efflux in leukemia cells. For LRP/MRP, The 
demonstration of drug efflux was, until now, not proven by transfection are antisense 
experiments (46). 
 
2.4.8 ATP-binding cassette sub-family G member 2 gene (ABCG2 
gene) 
Another member of the ABC superfamily is ABCG2, or breast cancer resistance 
protein (BCRP). BCRP is a 655- amino acid transmembrane protein coded on 
chromosome 4q21-22 (86). 
It was originally isolated from a breast cancer cell line, MCF-7Adrvp. A 95 KDa 
protein (P-95) was found to be increased in resistant cell line compared to the 
parental cell line (87).  
BCRP probably function as homodimer or a homotetramer (88). It is suspected 
that ABCG2 functions as a homodimer because transfection of the gene into 
cells confers resistance to chemotherapeutic drugs (89). Variations at residue 
482 of ABCG2 are found in many resistant cell lines, and the alteration of the 
wild-type arginine at this position for either threonine or glycine imparts the 
ability to transport rhodamine and alters the substrate specificity (90). 
 
 ʹͻ
It is highly expressed by normal stem cells (88), including hematopoietic cells 
(91), but its physiological role is not fully understood. Its abundant expression in 
human placenta (92) implies a role in fetal protection and its importance in 
protection against dietary compounds. In normal hematopiotic stem cells, the 
expression of BCRP decrease during differentiation, BCRP is also expressed by 
the so-called "leukemia stem cells" in AML, resulting in lower drug accumulation 
in these cells compared to more differentiated leukemia cells (93). 
Mitoxantrone, like doxorubicin and daunorubicin (94, 95), was initially shown to 
be a substrate of BCRP. The most important is the ability to extrude 
anthracyclines and mitoxantrone out side the leukemia cell. The expression and 
clinical importance of BCRP in leukemia patients have been studied in recent 















Table 2.3 Summary of previous studies relating MRP1, LRP and BCRP levels 
of expression and different leukemia types. 
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Materials and Methods 
 
3.1 Materials  
3.1.1 Reagents 
 







TaqMan two-step RT-PCR Master 





Lytic agent (cell Dyn 1700) Abbott  USA 
Guanidinium thiocynate  Sigma USA 
Phenol Sigma USA 
Chloroform  Sigma USA 
Isoamyle alcohol: Chloroform (1:49) Sigma USA 
Isopropanol Sigma USA 
Sodium acetate  Sigma USA 
Sodium citrate  Sigma USA 
Sarcosyle (10%) Sigma USA 
Gemsia stain  Sigma USA 
Methanol  Sigma USA 





3.1.2 Chemicals and buffers  
Table 3.2 Buffers used in the study. 
ID Composition 
Solution D Consist of 50 ml of guanidinium thiocynate (lysis solution) 
mix with 0.360 ml of Beta-Mercapto-ethanol; the solution is 
stable for 3 months. 
Sodium citrate (0.5 
M & Ph 7.0) 
14.7 gm dissolved in 70 ml H2O, pH adjusted 7 by (NaOH), 
the volume was completed to 100ml. 
Sarcosyle (10%) Weight 10 gm sarcosyle and dissolved in 100 ml H2O 
(DEPC water). 
Sodium acetate 
(2M & pH 4.0) 
16.4 gm dissolved in 100 mlH2O,adjust pH t0 4 by (HCL), 
complete the volume to 100ml. 
 
3.2 Instruments     





7500 Real Time PCR Applied Biosystem, USA 
Thermal Cycler Eppendrof, Germany 
Vortex Hettachi, Germany 
Microscope Olympus, Germany 
Micropipette 1--10 µL Hettachi, Germany 
Micropipette1--100 µL Hettachi, Germany 




Refrigerator (- 80 Cº) Revco, USA 
Ice container Eppendrof, Germany 
 
3.3 Ethical considerations  
All parts of the present study were performed in accordance with the Helsinki 
Declaration of 1975 (106). The approval letter for the present study was 
 
 ͵͵
obtained from the Helsinki committee and the Palestinian Ministry of Health 
(MOH) (Annex 1, 2). In addition, all the subjects involved in the present study 
gave there oral consent to be involved in the study.  
 
3.4 Target population   
This study is a cross sectional study involving a convenient sample within a 
definite time period. A study sample of 70 leukemia Palestinian patients was 
collected from both sexes who are admitted to the hematology departments of 
Al-Shefa hospital, European Gaza Hospital and EL-Nasser pediatric hospital of 
Gaza strip. A control sample of 35 healthy persons was collected from both 
sexes and matched age range of patients.  
 
3.5 Settings and place of work  
The practical parts of this work were performed in the Molecular Biology 
Department of the central laboratory, MOH and in the Biology Department 
laboratory of Islamic University of Gaza. 
 
3.6 Patients data  
Patient's medical data were collected from their records in the relevant 
hospitals. The data included personal, medical, management and family 
information (e.g. age, type of disease, severity of case, date of diagnosis of 
disease, treatment and types, protocols of treatments, prognosis, previous tests 
results and others) (Annex 3). 
 
3.7 Sample collection 
Samples were collected from both groups during a six-month period. All patients 
admitted to Hematology Departments who were newly diagnosis or diagnosed 
and treated according to leukemia protocols during the period 1/05/2009-
1/11/2009 were included. Two peripheral EDTA whole blood samples were 
collected from each case or control. One subjected to hematological 
investigation (CBC & blood film), and the second for Molecular investigations 




3.7.1 Hematological investigation 
  a. Complete blood count: The complete blood count (CBC) screening test 
has many applications, and it can help identify a wide variety of diseases. It is 
used to measure red blood cell and white blood cell count, total amount of 
hemoglobin in the blood, hematocrit (the amount of blood composed of red 
blood cells) and mean corpuscular volume (the size of red blood cells). Results 
can help detect problems such as dehydration or loss of blood, abnormalities in 
blood cell production and life span, as well as acute or chronic infection, 
allergies, and problems with clotting. The test was performed by using blood cell 
analyzer (cell Dyn 1700, from Abbott Company). 
  b. Blood Films:  A blood film or peripheral blood smear is a slide made from a 
drop of blood that allows the cells to be examined microscopically. Blood films 
are usually done to investigate hematological problems (disorders of the blood 
cells).  
A Blood films for each patient was made by placing a drop of blood on one end 
of a slide, and using a spreader slide to disperse the blood over the slide's 
length. The aim is to get a region where the cells are spaced far enough apart 
to be counted and differentiated. 
The slide was left to air dry, after which the blood was fixed to the slide by 
immersing it briefly in methanol. The fixative is essential for good staining and 
presentation of cellular detail. After fixation, the slide was stained with Geimsa 
stain to distinguish the cells from each other. 
3.7.2 Molecular investigation 
a. RNA extraction 
Total RNA was extracted from white blood cells (WBCs) using chomczynski 





Procedure of extraction 
Half ml of EDTA whole blood was placed in 2ml eppendorf tube and 1.5 ml lytic 
agent reagent was added and mixed by inversion 3 times. The sample was 
incubated on ice for 10-15 minutes, and vortexed two times during incubation. 
The sample was centrifuged at 400xg at 4Cº for 10 minutes. The supernatant 
was discarded completely and then the sediment resuspended in 1ml lytic agent 
by vortex mixing. It was centrifuged at 400xg at 4Cº for 10 minutes. After 
formation of pellet the supernatant was removed completely,   the WBCs pellet 
was resuspended with 1ml of solution D (see chemicals & buffers) and mixed by 
pipetting. 0.1ml of solution (2 M sodium acetate pH 4.o) was added to the 
mixture, mixed by inversion. 1ml phenol was added to the mixture and mixed by 
inversion, and then 0.2 ml chloroform: Isoamyle alcohol (49:1) was added and 
mixed by inversion. The mixture was shacked vigorously for 10 minutes by 
vortex, and incubated on ice for 15 minutes. The tube was centrifuged at 
10000xg for 20 minutes at 4Cº and the upper aqueous phase was transferred to 
a new 1.5 ml tube containing 1ml Isopropanol and mixed by inversion. The tube 
was incubated at -70 Cº for 20 minutes, and then centrifuged at 10000xg for 20 
minutes at 4 Cº. The supernatant was discarded completely and the pellet was 
resuspended in 0.3 ml solution D. 0.3 ml of Isopropanol was added to the 
solution then the mixture was incubated at -70 Cº for 15 minutes. The sample 
was Centrifuged 10000xg at 4Cº for 10 minutes and the supernatant was 
completely discarded. The pellet was resuspended in 75% ethanol 0.5 ml and 
centrifuged at 10000xg at 4Cº for 5 minutes. The supernatant was completely 
discarded, the tube was  air dried for 15 minutes at room temperature and 
dehydrated with 50 µL of H2O ( nuclease free water) at 65 Cº for 10 minutes, 
the sample was stored at -70 Cº. 
b. Quantitative RT-PCR (Reverse transcriptase-polymerase chain reaction) 
 The cDNA synthesis from total RNA was performed using TaqMan Reverse 
Transcription Reagents kit (Applied Biosystem, USA). A separate PCR reaction 
was preformed using previously published specific primers and protocols for 
each of the genes (MRP1, LRP, and BCRP) with modifications. The applied 
protocol was performed using the SYBR Green RT-PCR Reagents Kit (Applied 
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Biosystem, USA) containing: SYPR Green PCR Master Mix and TaqMan 
Reverse Transcription Reagents. 
cDNA Synthesis 
Synthesis of cDNA from 500ng total RNA samples was preformed in 10 µL 
volumes including 1x of the provided buffer, 5.5 mM MgCL2, 500 µM of each 
dNTPs, 2.5 µM of Random Hexamers, 0.4 u/l RNase Inhibitor and 1.25 u/l 
MultiScribe Reverse Transcriptase. 
The reaction was incubated for 10 minutes at 25 Cº, followed by 48 minutes at 
48 Cº and inactivation of the reverse transcriptase for 5 minutes at 95 Cº. 
 
SYBR Green based quantization of targets transcripts 
The SYBR Green PCR Master Mix, optimized for real-time PCR analysis, 
conveniently combines SYBR Green 1 Dye, AmpliTaq Gold DNA Polymerase, 
dNTPs with dUTP, Passive Reference dye, and optimized buffer components in 
easy-to-use premix vials. SYBR Green I dye detects double-stranded DNA, and 
the Passive Reference dye is required for signal normalization.  
The incorporation of SYBR Green I dye into a real-time PCR reaction lets detect 
any double-stranded DNA generated during PCR. This provides great flexibility 
because no target specific probes are required, and yet both specific and non-
specific products will generate a signal. The use of the hot-start enzyme 
AmpliTaq Gold DNA Polymerase with SYBR Green I reagent minimizes non-
specific product formation. SYBR Green I dyes are ideal for use in target 
identification (screening assays), or when only a small number of reactions are 
required for a given assay. 
Primers Selections 
All primer pairs sequences were obtained from a previously published work in 























































































Real Time PCR amplification reaction 
All reactions were carried out in 20 µL final volumes using the Applied 
Biosystems 7500 analyzer, USA. Five milliliter of previously prepared CDNA 
containing about 20ng of RNA, were combined with 15 µL of premixed reaction 
component, containing: 225 nM of each primer and (1X) of the Sybr green 





Table 3.5 A list of stages and temperature by time of RT-PCR amplification 
reaction. 
Stage Temperature Time # of Cycle 
1 50.0 Cº 2:00 min. 1 
2 95.0 Cº 10:00 min. 1 
3 95.0 Cº 0:15 min. 40 
 60.0 Cº 1:00 min.  
4 (Dissociation) 95.0 Cº 0:15 min. 1 
 60.0 Cº 1:00 min.  
 95.0 Cº 0:15 min.  
 60.0 Cº 0:15 min.  
 
Quantitation 
The quantitation standards used for the 4 targets (MRP1, LRP, BCRP and 
internal control Porphobilinogen deaminase (PBGD)) were prepared by 
qualitatively amplifying fragments of each using conventional PCR and then 
extraction purification of the amplicon from gel. The concentration of each 
amplicon was determined by spectrophotometer measurement of its optical 
absorbance at 260 nm using the NanoDrop (ND-1000 Spectrophotometer, 
NanoDrop Technologies Inc., USA). 
The number of copies of each amplicon was calculated from the concentration, 
molecular weight and Avogadro's number using the following equation: 
Molecule/ µL= (concentration/ molecular weight) X Avogadro's number. 
Serial dilutions of each standard were prepared and used for standard curve 
construction and quantitation of each target for each patients using standard 
curve quantitaion method. In order to correct for any errors or deviation in 
sample preparation or subsequent RT-PCR experiment, the quantitaion value 
for each target was normalized by division by the quantitaion value of the 




3.8 Biostatistics/ Data analysis 
The data was analyzed by the SPSS software (version 15). The one way 
ANOVA test was used for mean comparisons when indicated with a 95% 
confidence interval. The figures were prepared and presented by Microsoft 
office excel 2003 program.  
3.9 Limitations of the study: 
During the time of experimental work, the researcher had to repeat most of the 
work as a result of the bombardment of Laboratories building of the Islamic 
university during the aggressive Israeli intrusion to Gaza. For the same reason, 
the researcher had to repurchase the reagents again which increased the 
























4.1 Study population description 
4.1.1 Gender distribution 
A total of 105 samples were studied and divided into two groups: The first (case 
group) included 70 samples (57% were males and 43% females) from 
previously diagnosed leukemia patients (Figure 4.1). The second group 
(control) included 35 samples from normal healthy subjects (60% males and 








































Figure 4.2 Distribution of controls by gender. 
 
 
4.1.2 Living area 
Leukemia patients were distributed allover Gaza strip as follows: 11.4% from 
North Gaza, 41.4% from Gaza City, 4.2% from Middle Area, 32.9% from Khan 
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4.1.3 Age distribution 
The mean age of cases was 32.9 ±28.2 years and the mean age of controls 
was 27.2 ±18.8 years. 
The leukemia patients were divided into age groups according to age range of 
incidence of each type of leukemia as follows: 33 patients (47.1%) were < 15 
years old, 2 patients (2.9%) were 16-35 years old, 5 patients (7.1%) were 36-45 
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Figure 4.4 Distribution of cases by age groups. 
 
4.1.4 Case distribution according to place of sample collection 
The patient samples were collected from leukemia patients admitted to 
Hematology Departments of the three hospitals in Gaza Strip which were EL 
Shefa Hospital (13 cases, 18.6%), European Gaza Hospital (28 cases, 40%) 




























4.1.5 Distribution of cases by type of leukemia. 
Five types of leukemia were included in this study. Thirty cases (42.9%) were 
acute lymphoblastic leukemia, 5 cases (7.1%) were acute myeloblastic 
leukemia, 12 cases (17.1%) were chronic lymphoblastic leukemia, 22 cases 
(31.4%) were chronic myeloblastic leukemia and 1 case (1.4%) was small 




































Figure 4.6 Distribution of cases by type of leukemia. 
 
 
The diagnosis of each type of leukemia was confirmed by blood film at time of 








Figure 4.7 A representative microphotograph of a blood film showing blast  cells: 
(A) A myeloblast cell in AML case, (B) Blast cells in CLL case, (C) A metamyelocyte 
cell in CML case and (D) Lymphocyte cells in ALL case. The blast cells in all types are 
pointed by arrows. 
 
 
4.1.6 Types of cases management 
Out of the 70 patients, 65 cases (92.9%) received chemotherapy for leukemia 
management, whereas 5 cases (7.1%) received chemotherapy and bone 

























Figure 4.8 Distribution of cases by type of managements. 
 
Out of the 70 patients, the 30 case (42.9%) affected with Acute Lymphoblastic 
Leukemia (ALL) were treated according to Standard Berlin-Frankfurt-Munster 
Study Group protocol (BFM-ALL) (Annex 4). All ALL patients received 
Prednisone (60 mg/M²), Vincristine (2 mg/M²), L-asparaginase (5,000 unites/ 
M²), 6-mercaptopurine (6-MP) (50 mg/ M² /day/2years), and Methotrexate (20 
mg/ M² /weekly/2 years). 
The Five cases (7.1%) of acute myeloblastic leukemia (AML) were treated 
according to a protocol that contains two phases of treatments: Induction phase 
and Consolidation phase. Also relapsed and refractory disease was treated 
according to high-dose cytarabine (Ara-C) /Mithoxantrone (HAM) protocol 
(Annex 5). The drugs used in AML treatment were Cytosar (100 mg/m²), 
daunorubcine (45 mg/m²), Fludarabine (30 mg/m²) and Mitoxantrone (12 
mg/m²). 
The Twelve (17.1%)  Chronic Lymphoblastic Leukemia (CLL) cases received 
Fludarabine (25 mg/m²), Cyclophosphomide (40mg/m²), vincristine (1.4mg/m²), 
Prednisone (80mg/m²) and Chrorambucil (0.1mg/kg/day). Every patient 
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received different types of these drugs according to situation case and 
according to protocol (Annex 6). 
 The 22 cases (31.4%) of Chronic myeloblastic leukemia (CML) received the 
following drugs as a CML regimen protocol (Annex 7): Interferon-Alfa 2a (IFN) 
(5 million unite/m²/day), Hydroxyurea (500mg/day), Cytosine arabinoside 
(Cytosar) (500mg/day), Imatinib mesylate (Gleevec) (300mg/day) and Busulfan 
(4 mg/m²/day). 
The Small lymphocytic leukemia (SLL) received the drugs Fludarabine 
(25mg/m²) 3 days, and Cyclophosphoamide (40 mg/m²) 3 days. Combination 
between the two drugs and was repeated every 28 days and prednisone (80 
mg/m²) (Annex 8). 
 
 
4.2 Quantitation of drug resistance. 
4.2.1 Validation of Syber-green quantitation experiments. 
Standard curves were constructed from mean cycle threshold (CT) values 
obtained from at least 4 separated experiments.  The regression and slopes of 




Figure 4.9-A the standard curve of PBGD gene. 
 













As with all Syber green quantitation experiments the stringency of reactions 
must be increased in order to reduce non specific amplification that may 
represent a bias in quantitation values. Therefore, the primers concentration 
and templates amount were optimized and melting curves for the product of 
each target were evaluated (Figure 4.10 4.13). No noticeable non specific 
amplification was present in the final reactions. 
However, this high stringency requirement resulted in reduced sensitivities of 
the test. The detection limit of MRP1 and LRP PCR was 10³ copies and for 




Figure 4.10 Dissociation curves of PBGD gene in case samples: 







Figure 4.11 Dissociation curves of MRP1 gene in case samples: 




Figure 4.12 Dissociation curves of LRP gene in case samples: 





Figure 4.13 Dissociation curves of BCRP gene in case samples: 
The x--axis Temperature Cº and y-axis fluorescence value. 
 
The samples were found negative for MRP1 gene in eight cases (11.4%) of 
leukemia, and no negative samples in controls, for LRP gene 12 (17.1%) 
samples were negative in the cases and seven samples in controls, and 
31(44.9%) samples were negative in the cases and 15 samples in controls for 
BCRP gene expression. 
4.2.2 The levels of MRP1, LRP and BCRP drug resistance genes 
expression 
As previously indicated all gene expression values are represented as 
normalized copy number of gene RNA, calculated as number of copies of target 
gene RNA divided by number of copies of endogenous control gene RNA. The 
mean normalized copy number of MRP1 gene was significantly higher in cases 
compared to control (P value =0.007) (Table 4.1). Also, the mean normalized 
copy number of LRP gene was significantly higher in cases than in controls (P 
value= 0.007). In BCRP gene, the mean of normalized number of copies in 




Table 4.1 The mean number of copies to genes (MRP1, LRP & BCRP) in cases 
and controls. 




4.2.2.1 The levels of MRP1, LRP and BCRP genes expression by 
gender 
 
The gene expression levels of MRP1, LRP and BCRP genes in case group was 
generally higher in females compared to males. However this difference was 
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Table 4.2 The gene expression of MRP1, LRP & BCRP genes in male and 
female cases. 
                      ̅ P-value calculated by One-Way ANOVA analysis SPSS. 
 
 
4.2.2.2 The levels of MRP1, LRP and BCRP genes expression by age 
grouping. 
 
As mentioned previously, leukemia patients in the present study divided into 4 
categories according to age, when compared the levels of MDR genes 
expression between these groups. The age group < 15 years was lower than 
age group of patients 36-45 years, in both MRP1 and LRP genes respectively, 
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36-45 years -8.52 4.02 0.038  




36-45 years >45 years 5.98 4.02 0.142 
36-45 years -23.36 11.41 0.045  




36-45 years >45 years 15.97 11.38 0.166 
36-45 years 0.02 0.18 0.931 
<15 years 




36-45 years >45 years -0.06 0.18 0.758 
      P-value calculated by One-Way ANOVA analysis SPSS. 
 
 
4.2.3 MRP1 gene expression in different types of leukemia 
 
The mean MRP1 gene expression was significantly higher in all types of 
leukemia (except for ALL) than in control group (ALL: P=0.365, AML: P=0.000, 
CLL: P=0.037 and CML: P=0.010) (Table 4.4). 
The levels of MRP1 gene expression in different types of leukemia varied 
(Table 4.4). By comparing these types of leukemia, It was found that the mean 
difference of expression levels of ALL patients was significantly less than AML 
patients (P=0.001). The mean difference between ALL patients, CLL patients 
and CML patients was not significant. The mean difference in expression levels 
between AML patients higher than CLL patients and CML patients, and the 
increased statistically significant (CLL: p= 0.024 and CML: p = 0.017). 




Table 4.4 The mean difference of MRP1 gene expression between leukemia 
types & control. 
            ̅ P-value calculated by One-Way ANOVA analysis SPSS.   




4.2.4 LRP gene expression in different types of leukemia 
 
The mean LRP gene expression was significantly higher in AML patients and 
CML patients than in control group (AML: P=0.021 and CML: P=0.001). 
It was also higher in ALL and CLL patients than in control group but not 
statistically significant (Table 4.5).  
By comparing the LRP gene expression levels in leukemia types, It was found, 
that the mean difference of expression levels of ALL patients was less than 
CML patients and this decrease is statistically significant (P=0.024). The mean 
difference between ALL patients, AML and CLL patients in expression levels 
was not statistically significant. Also the mean difference between AML patients 
and CLL and CML patients was not statistically significant. The levels of LRP 
gene expression in CLL patients was less than in CML patients and this 










AML -11.92 3.49 0.001 
CLL -3.24 2.34 0.170 ALL 
 CML -3.24 1.93 0.097 
CLL 8.68 3.80 0.024 AML 
 CML 8.68 3.56 0.017 
CLL CML -0.01 2.44 0.998 
ALL -1.53 1.68 0.365 
AML -13.45 3.43 0.000 




 CML -4.77 1.82 0.010 
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Table 4.5 The mean difference of LRP gene expression between leukemia 







Difference (I-J) Std. Error 
Sig.(̅P 
value) 
AML -15.34 9.38 0.106 
CLL 1.46 6.54 0.823 ALL 
CML -12.26 5.33 0.024 
CLL 16.81 10.28 0.106 
AML 
CML 3.08 9.56 0.748 
CLL CML -13.72 6.79 0.046 
ALL -6.44 4.83 0.186 
AML -21.78 9.28 0.021 
CLL -4.98 6.40 0.439 
(control) 
Normal 
CML -18.70 5.16 0.001 
             ̅ P-value calculated by One-Way ANOVA analysis SPSS.   






4.2.5 BCRP gene expression in different types of leukemia 
 
The mean expression levels of BCRP gene was not statistically significant in all 
types of leukemia compared with control group (ALL: P=0.528, AML: P=0.953, 
CLL: P=0.557 and CML: P=0.088) (Table 4.6). 
The mean difference of BCRP gene levels between all types of leukemia was 







Table 4.6 The mean difference of BCRP gene expression between leukemia 
types and control. 
̅P value calculated by One-Way ANOVA analysis SPSS. 
                 -The mean difference is significant at the .05 level. 
 
 
Expression of each of the MDR genes in the study was independent of the 
WBCs count and blast cells count at sample of collections and living area. 
 
 
4.2.6 Leukemia managements and levels of gene expression 
 
When comparing the level of expression of the three genes (MRP1, LRP& 
BCRP) according to management protocols (chemotherapy & Bone Marrow 














AML 0.03 0.16 0.829 
CLL 0.10 0.10 0.312 
 ALL 
  
  CML -0.09 0.08 0.256 
CLL 0.07 0.17 0.697  AML 
  CML -0.13 0.16 0.443 









AML -0.01 0.16 0.953 






CML -0.14 0.08 0.088 
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Table 4.7 The relation between gene expression levels of MRP1, LRP& BCRP 
genes and leukemia managements. 
 
           ̅P-value calculated by One-Way ANOVA analysis SPSS. 




4.2.7 Remission and gene expression 
All patients received chemotherapy protocols for their leukemia managements, 
and only 5 patients underwent bone marrow transplantation (B.M.T) in addition 
to chemotherapy protocol. The number of cases that responded and showed 
good prognosis (remission) were 47 cases (67.1%), and 22 cases (31.4%) had 
bad prognosis with no remission. Also one case (1.4%) died. The mean 
expression levels of MRP1 gene and LRP gene in remission patients was less 
than no-remission patients and this decrease of expression was  statistically 
significant (MRP1: P=0.003 & LRP: P=0.050). The mean level of BCRP gene 
expression in remission patients was less than no-remission patients, but 
without statistical significance (Table 4.8).   





Chemotherapy 56 5.11 1.15 
Chemotherapy & Bone 
marrow transplantation 
5 4.59 3.52 
MRP1 gene 





Chemotherapy 52 13.28 3.13 
Chemotherapy & Bone 
marrow transplantation 
5 4.32 2.11 
LRP gene  




Chemotherapy 35 0.14 0.04 
Chemotherapy & Bone 
marrow transplantation 
3 0.09 0.05 
BCRP gene  






    
Table 4.8 The mean levels of gene expression of MRP1, LRP & BCRP genes in 
remission (Yes or No).     
Gene Remission N Mean Std. Error 
Sig.(̅p 
value) 
Yes 40 2.80 0.67 
No 21 9.39 2.68 
 
MRP gene 




Yes 36 8.27 2.99 
No 21 19.74 5.67 
 
LRP gene 
Total 57 12.49 2.88 
 
0.050 
Yes 26 0.10 0.03 
No 12 0.21 0.09 
 
BCRP gene 
Total 38 0.14 0.04 
 
0.191 
     ̅P-value calculated by One-Way ANOVA analysis SPSS. 
 
 
4.2.7.1 Remission and gender 
The total number of leukemia cases was 70 cases, among which 40 cases were 
male and 30 were females. The remission cases in male were 28 (70%) while 
12 cases (30%) had no remission. The female cases 19 cases (63.3%) were in 
remission while the other 11 cases (36.7%) not remission (Figure 4.14). The 
highest number of remission was in ALL patients (27 cases, 90%) and the 

























Figure 4.14 The relation between gender and remission in cases. 
 
Table 4.9 The remission among leukemia types. 
Remission  
Leukemia type Yes No 
 
Total 
Acute lymphoblastic leukemia (ALL) 27 3 30 
Acute myeloblastic leukemia (AML) 3 2 5 
Chronic lymphoblastic leukemia 
(CLL) 
6 6 12 
Chronic myeloblastic leukemia 
(CML) 
10 12 22 
Small lymphoblastic leukemia (SLL) 1 0 1 
Total 47 23 70 
                 
 
4.2.8 Drugs and levels of (MRP1, LRP & BCRP) gene expression 
All patients received chemotherapy protocols according to their type of 
leukemia. Many factors are considered in determining type and dosage of 
chemotherapeutic drug. Five families of chemotherapeutic drugs (explained in 
chapter 2) are alkylating agents, anti-metabolites, plant alkaloids, 
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topoisomerase inhibitors and anti-tumor antibiotics. All drugs administrated to 
patients in this study belong to these families (Annex 9-12). When the mean 
expression of MRP1, LRP and BCRP genes were compared between different 
types of chemotherapy drugs, no significant difference was found.  
4.3 Study Case 
For one of the patients included in this study and suffering from ALL, the 
number of WBCs at diagnosing was 93.9x10³ cell/ µL and 80% blast cells was 
found in peripheral blood. The patient was managed by chemotherapy for 36 
months; he initially was treated according to Standard Berlin-Frankfurt-Munster 
Study Group protocol (BFM-ALL). The treatment protocol included three 
phases:  
(1) Induction phase: 
a. Induction phase I: He received in induction phase 1 (Vincristine 2 mg, 
Prednisone 60 mg/M² & L-asporaginase 5X10³unites/M²). 
 b. Induction phase II: Also received (Cyclophosphamide 650mg/M², Cytarabine 
75 mg/ M² & 6-MP 60 mg/ M²). 
(2) Consolidation phase: 
a. Consolidation I: also received in consolidation phase I (Vincristine 2mg, 
Doxorubicin 25 mg/M² & Dexamethasone 10 mg/M²). 
B. consolidation phase II: (Cyclophosphomide 650 mg/M², Cytarabine 75 mg/M² 
& 6-Thioguanine 60 mg/M²). 
(3) Maintenance phase: He received 6-MP 60 mg/M² & Methotrexate 20 mg/M². 
He was complete the three phases. The blast cells at time of sample collection 
were 82% after 36 months of chemotherapy, at this time he become in relapsed 
case and received Etopsoide 100mg/M², Cyclophosphamide 750mg/ M², 
Aracytin 100mg/M², and high dose Methotrexate 6-gm/M². The levels of MRP1, 
LRP and BCRP gene expression were extremely high compared to other 
patients (MRP1 : 2774 normalized copy numbers compared to case mean (4.5), 
LRP: 1525 compared to case mean (10.3) and BCRP: 1.5 compared to case 









Although the antineoplastic drugs currently available are usually effective for the 
treatment of various tumors, they may prove to be relatively ineffective in the 
treatment of some primary or recurrent neoplasias. The identification of factors 
that might effectively predict response of the patient to treatment is a constant 
challenge in oncology. Cell resistance to drugs is a determinant of the response 
to chemotherapy, and its detection via RT-PCR may be of clinical importance. 
  
During the last decade, several studies have defined a role for expression of 
transmembrane carriers such as multidrug resistance related Protein (MRP1), 
breast cancer resistance protein (BCRP) and lung resistance protein (LRP) 
genes in neoplastic cell survival and risk of relapse for leukemia patients (97, 
99-103 & 108-110). 
 
The application of relatively simple techniques such as RT-PCR may be 
comparable to more sophisticated techniques such as biological methods in 
identifying the role of upregulation of these genes in resistance to 
chemotherapy. Therefore in this study we determined the level of expression of 
MRP1, BCRP, and LRP genes in cells of leukemia patients in Gaza strip by 
quantitative RT-PCR technique and its clinical significance as prognostic factors 
for the treatment outcome.  
In the present study, the case group was 70 samples (57% were males and 
43% females), the control group was 35 samples (60% males & 40% females). 
The main goal of control group inclusion was to correct for any expression 
difference between individuals as a result of gender and age difference. This 
group was also used to compare results from cases whenever possible, 
particularly because of the almost matched gender and age distribution.   
 
 ͸Ͷ
The study included living areas allover Gaza strip. The case group included five 
types of leukemia (42.9% ALL, 31.4% CML, 17.1% CLL, 7.1% AML and 1.4% 
SLL). 
The diagnosis was confirmed by blood film and other hematological 
investigation such as CBC.  
As shown in our results, there is significantly higher level of expression of MRP1 
and LRP genes among leukemia patients than normal control individuals. This 
result is in agreement with previously published studies (99-101 & 103, 104). 
However, our results of BCRP gene expression don't agree similarly. This may 
be due to low sensitivity of our BCRP RT-PCR experiments as evident from the 
relatively high number of negative cases and controls for the gene. 
As might be expected, these genes don't show any gender related difference in 
respect of their expression (Table 4.2).  The leukemia patients were divided into 
age groups according to previously described range of age onset of each type 
of leukemia. When the age groups of our study cases were compared, it was 
found that patients who are < 15 year's old show significantly lower MRP1 and 
LRP genes expression than other groups (Table 4.3). This may be due to the 
fact that the majority of this age group is comprised from ALL patients who 
show a lower level of MRP1 expression (Table 4.4)  than other types  of 
leukemia (such as AML: P=0.001). Moreover, ALL patients usually show higher 
rates of remission (about 75%) than other types (110).   
Also ALL patients' level of MRP1 gene expression was not significantly different 
from the normal control group, although it is slightly higher (Table 4.4). Other 
studies showed higher levels of MRP1 gene expression in ALL patients 
compared to normal (103, 104). 
When the level of expression of MRP1 was compared between the different 
leukemia types, the only statistically significant relation was established 
between AML, with higher expression and ALL with lower expression (Table 
4.4). This difference is in accordance with the results of other studies. For 
example, MRP1 gene expression was found to be higher in AML compared to 
ALL in Iranian patients (101). In the same study also the increased expression 
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in AML was correlated with poor outcome, in contrast to ALL. Other studies 
positively correlated the increased expression of MRP1 gene in increased 
relapse (99, 103 and 108). 
Likewise, when LRP gene expression was compared between the different 
types of leukemia as well as to the control group, significant correlations were 
found. First, both CML and AML showed significantly higher LRP level of 
expression than normal (Table 4.5), a result that is in consistence with other 
previous studies (95, 96, 99). 
It is well documented that expression of multiple drug resistance genes, 
particularly MRP1 and LRP, are involved in decreased remission rate (99, 100, 
101, 103 and 108). In this regard our results support such conclusion. We found 
a significantly decreased remission rate with expression of MRP1 and LRP 
genes in all types of leukemia. 
On the other hand, we found no significant difference in MRP1 and LRP gene 
expression in relation to the type of chemotherapeutic drugs used. This may be 
due to the fact that all patients suffering from the same type of leukemia were 
systematically managed using the same chemotherapeutic protocol, including 
the calculated dose and type of drug (see Annex 9-12). Only 5 patients were 
managed by BMT who also received the same chemotherapeutic agents as 
others at one stage of their disease progression. 
All in all, our results show that no matter, what the drug resistance gene is over-
expressed, the leukemia patient will suffer from an increased risk of relapse. 
This is evident by the fact that different leukemia types overexpress the MRP1 
and LRP genes to different extents. And at the same time they will relapse if 





Conclusions and Recommendations 
 
6.1 Conclusions 
 The overexpression of MRP1 and/ or LRP genes, among others genes like 
MDR1 gene, may represent a hallmark of different leukemia types, 
particularly if managed by chemotherapy. 
 No matter what drug resistance associated gene is overexpressed, the 
leukemia neoplasm will have an increased risk of relapse and finishing of 
therapy as a result. 
 Extremely high levels of a particular drug resistance associated gene alone 
or in combination with others, may be lethal due to non-responsiveness to 
treatment and the resulting toxicity associated with the demand of 
proportionally increase drug doses. 
 If to be used for prediction of treatment outcome, one has to expand the 
number of genes tested to cover all possibly overexpressed ones. 
Accordingly, a more comprehensive technique for testing, such as 
microarray technique, should be applied. 
 The proposed prognostic role of MRP1 and LRP in predicting chemotherapy 
outcome may be more profound in AML, CML and CLL patients but not ALL. 
  
6.2 Recommendations  
 The decisive role of MDR genes in response of patient to chemotherapy 
should be taken in consideration when planning for management protocols. 
 Profiling of level of expression of such genes in different leukemia types 
should be done, in order to establish diagnostic guidelines and protocols. 
 More studies should be conducted in which other MDR targets are analyzed 
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Annex 3                 
Patient's data 
Personal information 
□ Name:.    □ Age:   □ Weigh:.. 
□ Height: □ Place:. □ Occupation:. 
Medical information (This data will be completed from the patient medical record) 
1- Type of leukemia: 
     □ Acute lymphoblastic leukemia (ALL) 
    □ Acute myeloblastic leukemia (AML) 
    □ Chronic lymphoblastic leukemia (CLL) 
    □ Chronic myeloblastic leukemia (CML) 
    □ Acute Non-lymphoblastic leukemia (ANLL) 
    □ Promyelocytic leukemia(PL) 
2- Date at diagnosis: ..................................... . 
 
3- Hematological investigation at diagnosis date: 
          □ Leukocyte count . 
          □ Platelet count.. 
          □ Type of blast cell: Lymphoblast cell 
                                           Myeloblast cell 
4- Other investigation if applicable: 
     □ Imunophenotypic classification. 
     □ FAB classification. 
     □ Blood Film / Bone Marrow Aspiration / Biopsy. 
            Shown. 
     □ Karyotyping, PCR, FISH. 
            Shown. 
Management information 
1- Type of management: 
 
   □ Chemotherapy (Name and dosage of drug) 
    
 
 ͺ͵
   .... 
   □ Radiation 
   □ Bone Marrow Transplantation. 
   □ Other. 
   □ None. 
2- Duration of treatment. 
 
3- Date of last treatment. 
 
4- Is the patient currently in remission? 
                □ Yes            □ No 
              If yes, how long? 
               . 
5- Are you on any medication? 
        □ Yes            □ No   
6- Failure of treatment: 
        □ Yes            □ No   
       If yes, at time of relapse 
        □ WBCs count. 
        □ Blast cells count 
        □ Ratio of blast cells in Bone Marrow. 
Family information 
1- Is there a family history of cancer, in first degree relation? 
                     □ Yes            □ No   
     If yes, the degree of relation: 
                   □ Mother       □ Father      □ other relatives. 
2- Treatment: 
                     □ Yes            □ No   
- Current situation  
- Treatment succeed 
- Failure 












































































Annex 8: Chemotherapy protocol for SLL. 
 


















Annex 9: Data of ALL patients. (Management types & chemotherapy drugs). 
 





management Drug I Drug II Drug III Drug IV Drug V 
3 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
4 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
6 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
7 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
8 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
9 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
15 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
20 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
21 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
22 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
23 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
24 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
25 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
26 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
27 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
43 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
45 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
46 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
47 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
49 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
59 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
60 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
61 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
62 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
65 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
66 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
67 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
68 chemotherapy L-asparaginase vincrstine prednisone 6-MP MTX 
69 Chemotherapy 
& B.M.T 






















































































































Drug I Drug II Drug III Drug IV 
1 chemotherapy cyclophosphamide vincristine Prednisone Chlorambucil 
10 chemotherapy cyclophosphamide vincristine Prednisone Chlorambucil 
28 chemotherapy Fludarabine cyclophospha
mide 
vincristine prednisone 
30 chemotherapy cyclophosphamide vincristine prednisone chlorambucil 
31 chemotherapy cyclophosphamide fludarabine rituximab chlorambucil 
35 chemotherapy cyclophosphamide vincristine prednisone chlorambucil 
41 chemotherapy cyclophosphamide Fludarabine Rituximab ------- 
48 chemotherapy cyclophosphamide fludarabine rituximab chlorambucil 
52 chemotherapy cyclophosphamide vincristine Prednisone Chlorambucil 
53 chemotherapy cyclophosphamide vincristine prednisone ------- 
56 chemotherapy cyclophosphamide Fludarabine Rituximab ------- 
CLL 






































Drug I Drug II Drug III Drug IV Drug V 
5 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 




Busulfan Cytarabine Gleevec Interferon-a 
14 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
16 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
17 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
19 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
29 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
32 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
33 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
34 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
36 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
37 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
38 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
39 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 




Busulfan Cytarabine Gleevec Interferon-a 
42 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
44 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
50 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
54 chemotherapy Hydroxyu
rea 
Busulfan Cytarabine Gleevec Interferon-a 
55 chemotherapy Hydroxyu
rea 


















Busulfan Cytarabine Gleevec Interferon-a 
 
 
